CTRI/2024/04/065728招募中1 期
A Phase 1, First-in-Human, Multicenter, Open-Label, Dose Escalation and Dose-Expansion Study of Single-Agent ISB 2001 in Subjects with Relapsed/Refractory Multiple Myeloma. - NI
试验速览
- 阶段
- 1 期
- 状态
- 招募中
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1. Participants with pathologically confirmed MM with measurable M-protein: serum and/or 24-hour urine, serum-free light chains or measurable isolated plasmacytoma.
- •2. Have an Eastern Cooperative Oncology Group (ECOG) performance status score of 2 or less.
- •3. Must have adequate hematologic, hepatic, renal, and cardiac functions.
排除标准
- •1. Active malignant central nervous system involvement
- •2. Uncontrolled infection requiring systemic antibiotic therapy or other serious infection prior to C1D1
- •3. History of autoimmune disease requiring systemic immunosuppressive therapy
- •4. Any concurrent or uncontrolled medical, comorbid, psychiatric or social condition that would limit compliance with study procedures, interfere with the study results, substantially increase the risk of AEs, compromise ability to provide written informed consent or, in the opinion of the Investigator, constitute a hazard for participating in this study.
- •5. Female subjects who are lactating and breastfeeding or have a positive pregnancy test during the screening period or on Day 1 before first dose of ISB 2001.
研究者
相似试验
招募中
1 期
Phase I Dose Finding Study in Patients with HER2-Positive Advanced Solid TumorsHER2-Positive Advanced Solid TumorsCancer - Any cancerACTRN12620000592943Conjugate Light (Australia) Pty Ltd13
撤回
1 期
A First-In-Human, Dose Escalation and Expansion Study of GQ1007 Alone and in Combination with Envafolimab in Subjects with HER2-expressing Advanced Solid TumorsSolid TumorsCancer - Any cancerACTRN12622000513718GeneQuantum Healthcare (Suzhou) Co., Ltd.200
终止
1 期
A Phase 1 First in Human, Multicenter, Open-Label Dose-Escalation Study to Determine the Safety, Tolerability, Pharmacokinetics, and RP2D of ABBV-184 in Subjects with Previously Treated Cancers [M19-747]JPRN-jRCT2080225199AbbVie G.K24
招募中
1 期
Study to Determine the Safety, Tolerability, Pharmacokinetics and RP2D of ABBV-151 as a Single Agent and in Combination With ABBV-181 in Subjects With Locally Advanced or Metastatic Solid TumorsSolid Tumors, Locally Advanced or Metastatic Solid TumorsMedDRA version: 20.0Level: LLTClassification code: 10025648Term: Malignant mast cell tumors unspecified site extranodal and solid organ sites Class: 10029104CTIS2023-508281-15-00AbbVie Deutschland GmbH & Co. KG290
招募中
不适用
A Phase I, first-in-human, multicenter, open-label, dose escalation followed by an expansion phase clinical study of KBA1412 given as monotherapy or in combination with pembrolizumab in adults with advanced solid malignant tumorsmelanomaSolid Tumors10018865NL-OMON53468Kling Biotherapeutics B.V.22